Yun-Qiang Tang
Overview
Explore the profile of Yun-Qiang Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang C, Zhang X, Yuan J, Gong Y, Tang H, Guo W, et al.
J Vis Exp
. 2023 Aug;
(198).
PMID: 37607105
Hepatocellular carcinoma (HCC) is a highly prevalent and lethal tumor worldwide and its late discovery and lack of effective specific therapeutic agents necessitate further research into its pathogenesis and treatment....
2.
Cheng W, Li H, Xi S, Zhang X, Zhu Y, Xing L, et al.
Nat Commun
. 2021 Dec;
12(1):7142.
PMID: 34880251
Tumour lineage plasticity is an emerging hallmark of aggressive tumours. Tumour cells usually hijack developmental signalling pathways to gain cellular plasticity and evade therapeutic targeting. In the present study, the...
3.
Kong F, Li G, Tang Y, Xi S, Loong J, Li M, et al.
Sci Transl Med
. 2021 Feb;
13(579).
PMID: 33536280
Tumor lineage plasticity is emerging as a critical mechanism of therapeutic resistance and tumor relapse. Highly plastic tumor cells can undergo phenotypic switching to a drug-tolerant state to avoid drug...
4.
Tang Y, Chen T, Zhang Y, Zhao X, Zhang Y, Wang G, et al.
Gastroenterol Rep (Oxf)
. 2020 Nov;
8(5):381-389.
PMID: 33163194
Background: Biomarkers based on immune context may guide prognosis prediction. T-cell inactivation, exclusion, or dysfunction could cause unfavorable tumor microenvironments, which affect immunotherapy and prognosis. However, none of the immuno-biomarkers...
5.
Ma Z, Gong Y, Zhuang H, Zhou Z, Huang S, Zou Y, et al.
World J Gastroenterol
. 2020 Jun;
26(19):2305-2322.
PMID: 32476795
Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of tumors with complicated treatment options that depend on pathological grading, clinical staging, and presence of symptoms related to hormonal secretion. With...
6.
Kong F, Tang Y, Gong Y, Mo J, Zhao Y, Li M, et al.
Hepatol Int
. 2020 Apr;
14(4):521-533.
PMID: 32304089
Background: Loss of terminal differentiation markers and gain of stem cell-like properties are a major hallmark of cancer malignant progression. Identification of novel biomarkers representing tumor developmental progeny and predictive...
7.
Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong J, et al.
Proc Natl Acad Sci U S A
. 2020 Mar;
117(11):6103-6113.
PMID: 32123069
Clinical observation of the association between cancer aggressiveness and embryonic development stage implies the importance of developmental signals in cancer initiation and therapeutic resistance. However, the dynamic gene expression during...
8.
Ba M, Long H, Zhang X, Gong Y, Tang Y, Wu Y, et al.
Surg Laparosc Endosc Percutan Tech
. 2020 Feb;
30(1):55-61.
PMID: 32004214
Background: To compare the efficacy of 3 chemotherapeutic combinations for laparoscopic hyperthermic intraperitoneal perfusion chemotherapy (HIPPC) in the treatment of malignant ascites secondary to unresectable gastric cancer (GC). Materials And...
9.
Li M, Tang Y, Gong Y, Cheng W, Li H, Kong F, et al.
BMC Cancer
. 2019 Aug;
19(1):851.
PMID: 31462277
Background: Gradual loss of terminal differentiation markers and gain of stem cell-like properties is a major hall mark of cancer malignant progression. The stem cell pluripotent transcriptional factor SOX family...
10.
Fang J, Xu L, Shang L, Pan C, Ding J, Tang Y, et al.
Hepatology
. 2018 Dec;
70(3):824-839.
PMID: 30506570
Sorafenib is the most recommended first-line systemic therapy for advanced hepatocellular carcinoma (HCC). Yet there is no clinically applied biomarker for predicting sorafenib response. We have demonstrated that a vascular...